Leyre López-Soria

Leyre López-Soria

Auto-generated profile, based on publicly available information

Leyre López-Soria

Clinical Microbiology Department, Hospital Universitario Cruces, Barakaldo, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2018 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
ARAndoni Ramirez-Garcia
Andoni Ramirez-Garcia
APAize Pellon
Aize Pellon
Aitor RementeriaAitor Rementeria
Aitor Rementeria
IBIdoia Buldain
Idoia Buldain
EBEliana Barreto-Bergter
Eliana Barreto-Bergter
FHFernando L Hernando
Fernando L Hernando
Species of Scedosporium and Lomentospora are considered as emerging opportunists, affecting immunosuppressed and otherwise debilitated patients, although classically they are known from causing trauma-associated infections in healthy individuals. Clinical manifestations range from local infection to pulmonary colonization and severe invasive disease, in which mortality rates may be over 80%. These unacceptably high rates are due to the clinical status of patients, diagnostic difficulties, and to intrinsic antifungal resistance of these fungi. In consequence, several consortia have been founded to increase research efforts on these orphan fungi. The current review presents recent findings and summarizes the most relevant points, including the Scedosporium/Lomentospora taxonomy, environmental distribution, epidemiology, pathology, virulence factors, immunology, diagnostic methods, and therapeutic strategies.

1 June 2018 in JACC
Verified
Journal Article
Closed access
IZIsabel Zegri-Reiriz
Isabel Zegri-Reiriz
AAArístides de Alarcón
Arístides de Alarcón
PMPatricia Munoz
Patricia Munoz
MSManuel Martínez Sellés
Manuel Martínez Sellés
CRClaudia Gonzalez Rico
Claudia Gonzalez Rico
JLJuan Carlos Segura Luque
Juan Carlos Segura Luque

1 June 2019 in European Journal of Internal Medicine
Verified
Journal Article
Open access
CACarlos Armiñanzas
Carlos Armiñanzas
MÁMaría Concepción Fariñas Álvarez
María Concepción Fariñas Álvarez
JZJesús Zarauza
Jesús Zarauza
PMPatricia Munoz
Patricia Munoz
VRVíctor José González Ramallo
Víctor José González Ramallo
JLJuan Carlos Segura Luque
Juan Carlos Segura Luque
The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32-3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39-1.88),and non-performed surgery (HR:1.64;95% CI:11.16-1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group.

1 October 2013 in Revista Iberoamericana de Micologia
Verified
Journal Article
Closed access
JGJuan Carlos García-Ruiz
Juan Carlos García-Ruiz
LLLeyre López-Soria
Leyre López-Soria
IOIñigo Olazábal
Iñigo Olazábal
EAElena Amutio
Elena Amutio
IAInés Arrieta-Aguirre
Inés Arrieta-Aguirre
MMMaria Dolores Moragues
Maria Dolores Moragues

1 January 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
AEAna Espinel-Ingroff
Ana Espinel-Ingroff
JTJ. Turnidge
J. Turnidge
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
FBF. Botterel
F. Botterel
ECE. Canton
E. Canton
MTM. Tejada
M. Tejada
Although the Sensititre Yeast-One (SYO) and Etest methods are widely utilized, interpretive criteria are not available for triazole susceptibility testing of Candida or Aspergillus species. We collected fluconazole, itraconazole, posaconazole, and voriconazole SYO and Etest MICs from 39 laboratories representing all continents for (method/agent-dependent) 11,171 Candida albicans , 215 C. dubliniensis , 4,418 C. glabrata species complex, 157 C. guilliermondii ( Meyerozyma guilliermondii ), 676 C. krusei ( Pichia kudriavzevii ), 298 C. lusitaniae ( Clavispora lusitaniae ), 911 C. parapsilosis sensu stricto , 3,691 C. parapsilosis species complex, 36 C. metapsilosis , 110 C. orthopsilosis , 1,854 C. tropicalis , 244 Saccharomyces cerevisiae , 1,409 Aspergillus fumigatus , 389 A. flavus , 130 A. nidulans , 233 A. niger , and 302 A. terreus complex isolates.

26 July 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
IMIlargi Miranda-Zapico
Ilargi Miranda-Zapico
EEElena Eraso
Elena Eraso
JHJosÉ Luis HernÁNdez-Almaraz
JosÉ Luis HernÁNdez-Almaraz
LLLeyre MÓNica LÓPez-Soria
Leyre MÓNica LÓPez-Soria
ACAlfonso Javier Carrillo-MuÑOz
Alfonso Javier Carrillo-MuÑOz
Guillermo QuindósGuillermo Quindós
Guillermo Quindós
There is scarce information on the clinical relevance and antifungal susceptibility of Candida bracarensis, Candida nivariensis, Candida orthopsilosis and Candida metapsilosis. The objective of this study was to assess the prevalence and in vitro antifungal susceptibility of these cryptic species among 173 blood isolates previously identified as Candida glabrata or Candida parapsilosis at the Hospital of Cruces (Barakaldo, Spain). The survey was extended to 518 clinical isolates from the culture collection of the Universidad del País Vasco-Euskal Herriko Unibertsitatea (UPV-EHU; Bilbao, Spain). In vitro susceptibilities to 5-fluorocytosine, amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, micafungin, posaconazole and voriconazole were tested. All isolates of C. glabrata were identified as C. glabrata sensu stricto. Inside the C. parapsilosis complex, 2.4% of isolates from the Hospital of Cruces and 5.8% from the UPV-EHU were C. metapsilosis or C. orthopsilosis. Of 457 isolates, 435 (95.19%) were C. parapsilosis sensu stricto, 11 (2.41%) C. metapsilosis and 11 (2.41%) C. orthopsilosis. Only seven blood isolates were C. metapsilosis (0.44%) or C. orthopsilosis (1.09%). These cryptic species were also isolated from other relevant clinical specimens. Four C. parapsilosis sensu stricto (5.6%) were susceptible dose-dependent, and one was resistant to both fluconazole and voriconazole (1.4%). Moreover, 19 isolates of C. parapsilosis sensu stricto (26.4%) were intermediately susceptible to itraconazole and higher concentrations of echinocandins were needed to inhibit this species. Most C. orthopsilosis and C. metapsilosis were susceptible to all antifungal agents tested, but one otic isolate of C. metapsilosis was resistant to fluconazole and 5-fluorocytosine. C. metapsilosis and C. orthopsilosis are associated with human disease and show a different antifungal susceptibility profile compared with C. parapsilosis sensu stricto.